We recently announced our first biotech investment at USV in a company called Humane Genomics. They engineer viruses that can be made to selectively infect different kinds of cells. To start, they’re focused on viruses that kill cancer cells (“oncolytic viruses”). The first oncolytic viral therapy to be approved in the US was in 2015. […]
